HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Personal Care Products In Court: Clinique May Settle Probiotic Suit; ‘99.99% Of Germs’ Sanitizer Update

Executive Summary

The latest on proposed false-advertising class actions targeting Clinique Laboratories for probiotic representations and leading hand sanitizer manufacturers for “kills 99.99% of germs” claims.

You may also be interested in...



ACI’s Antiseptic Testing Continues Under Specter Of FDA Administrative Order

The American Cleaning Institute is preparing to submit a healthcare personnel hand wash study to the US FDA pending confidentiality discussions, along with results from a literature review on the topic of antimicrobial resistance. A progress report is due to the agency in October, which could stave off an administrative order under the reformed OTC drug review system.

Clinique Probiotic Claims Challenged In Proposed US Class Action

The false advertising case in New York federal court is one to watch for any cosmetics company using probiotic claims. Are consumers of “probiotic”-containing cosmetics getting what they reasonably expect?

Edgewell Seeks Dismissal Of Wet Ones ‘99.99%’ Germ-Kill Suit

The US FDA has primary jurisdiction over labeling claims on OTC consumer antiseptic rubs, and state false advertising claims lodged by the plaintiff are preempted by federal law, Edgewell Personal Care argues in its motion to dismiss a proposed class action in California federal court regarding Wet Ones germ-killing claims.

Related Content

Topics

UsernamePublicRestriction

Register

RS151369

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel